Ahmet ÖZET, Dilek YAPAR, Hasan SATIŞ, Neslihan KAYAHAN, Mustafa KARACA

Folfirinox versus gemcitabine-cisplatin combination as first-line therapy in treatment of pancreaticobiliary cancer

Background/aim: The purpose of this study was to compare efficacy and safety of a combination chemotherapy regimen consisting of oxaliplatin, irinotecan, fluorouracil, and leucovorin (FOLFIRINOX) and gemcitabine-cisplatin as first-line therapy in patients with pancreatic cancer. Materials and methods: Pancreaticobiliary cancer patients who had Eastern Cooperative Oncology Group performance status score of 0 or 1 (on a scale of 0 to 5, with higher scores indicating greater severity of illness) were evaluated to receive folfirinox or gemcitabine plus cisplatin. The primary endpoints were progression-free and overall survival time. Safety analysis was also evaluated as secondary measures. Results: There were 32 patients in the folfirinox group and 36 patients in the gemcitabine-cisplatin group. The median overall survival was 18.1 months (7.5–28.7) in the folfirinox group as compared with 9.7 months (6.5–13) in the gemcitabine-cisplatin group (p = 0.009). Median progression-free survival was 16.2 months (9–23.4) in the folfirinox group and 6.9 months (6.1–7.6) in the gemcitabinecisplatin group (p = 0.001).Conclusion: Folfirinox is an option for the first-line treatment of patients with pancreatic cancer and good performance status.Key words: Pancreatic cancer, folfirinox, gemcitabine-cisplatin, effectiveness, side effect

PDF

___

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA: A Cancer Journal for Clinicians, 2013; 63(1): 11-30. doi: 10.3322/caac.21166
2. Aroldi F, Bertocchi P, Savelli G, Rosso E, Zaniboni A. Pancreatic cancer: New hopes after first line treatment. World Journal of Gastrointestinal Oncology 2016; 8(9): 682-687. doi: 10.4251/wjgo.v8.i9.682
3. Asuthkar S, Rao JS, Gondi CS. Drugs in preclinical and earlystage clinical development for pancreatic cancer. Expert Opinion on Investigational Drugs 2012; 21(2): 143-152. doi: 10.1517/13543784.2012.651124
4. Heinemann V, Haas M, Boeck S. Systemic treatment of advanced pancreatic cancer. Cancer Treatment Reviews 2012; 38(7): 843-853. doi: 10.1016/j.ctrv.2011.12.004
5. Wang YH, Zhang GF, Qian Q, Ning T, Jun G et al. Efficacy and safety of gemcitabine plus erlotinib for locally advanced or metastatic pancreatic cancer: A systematic review and metaanalysis. Drug Design, Development and Therapy 2016; 10: 1961-1972. doi: 10.2147/DDDT.S105442
6. Rothenberg M, Moore MJ, Cripps MC, Andersen JS, Portenoy RK et al. A phase II trial of gemcitabine in patients with 5-FUrefractory pancreas cancer. Annals of Oncology, 1996; 7(4): 347-353. doi: 10.1093/oxfordjournals.annonc.a010600
7. Burris HRM, Malcolm J, Andersen J, Green MR, Rothenborg ML et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. Journal of Clinical Oncology 1997; 15(6): 2403-2413. doi: 10.1200/ JCO.1997.15.6.2403
8. Suker MB, Berend R, Sadot E, Marthey L, Faris JE et al. FOLFIRINOX for locally advanced pancreatic cancer: A systematic review and patient-level meta-analysis. The Lancet Oncology 2016; 17(6): 801-810. doi: 10.1016/S1470- 2045(16)00172-8
9. Ciliberto DB, Cirino C, Pierpaolo, Rossi M, Caraglia M et al. Role of gemcitabine-based combination therapy in the management of advanced pancreatic cancer: A meta-analysis of randomised trials. European Journal of Cancer 2013; 49(3): 593-603. doi: 10.1016/j.ejca.2012.08.019
10. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). European Journal of Cancer 2009; 45(2): 228-247. doi: 10.1016/j.ejca.2008.10.026
11. Colucci G, Francesco G, Vittorio G, Biglietto M, Rabitti P et al. Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: A prospective, randomized phase III study of the Gruppo Oncologico dell’Italia meridionale. Cancer 2002; 94(4): 902-910. PMID: 11920457
12. Colucci G, Roberto L, Francesco C, Gebbia V, Carteni G et al. Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: The GIP-1 study. Journal of Clinical Oncology 2010; 28(10): 1645-1651. doi: 10.1200/JCO.2009.25.4433
13. Chao, YW, Wang CH, Jack P, Lee RC, Lee WP et al. A randomized controlled trial of gemcitabine plus cisplatin versus gemcitabine alone in the treatment of metastatic pancreatic cancer. Cancer Chemotherapy and Pharmacology 2013; 72(3): 637-642. doi: 10.1007/s00280-013-2239-1
14. Inal A, Koş FT, Algin E, R Yıldız, Dikiltaş M et al. Gemcitabine alone versus combination of gemcitabine and cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: A retrospective analysis of multicenter study. Neoplasma 2012; 59(3): 297-301. doi: 10.4149/ neo_2012_038
15. Herrmann R, Bodoky G, Ruhstaller T, Glimelius B, Bajetta E et al. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: A randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. Journal of Clinical Oncology 2007; 25(16): 2212-2217. doi: 10.1200/JCO.2006.09.0886
16. Ychou MC, Conroy T, Seitz JF, Gourgou S, Hua A et al. An open phase I study assessing the feasibility of the triple combination: oxaliplatin plus irinotecan plus leucovorin/5-fluorouracil every 2 weeks in patients with advanced solid tumors. Annals of Oncology 2003; 14(3): 481-489. doi: 10.1093/annonc/mdg119
17. Conroy T, Paillot B, François E, Bugat R, Jacob JH et al. Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer-a Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer study. Journal of Clinical Oncology 2005; 23(6): 1228-1236. doi: 10.1200/JCO.2005.06.050
18. Conroy TD, Desseigne F, Marc Y,Bouche O, Guimbaud R et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. New England Journal of Medicine 2011; 364(19): 1817- 1825. doi: 10.1056/NEJMoa1011923
19. Zhang SHL, Li GF, Liu XF, Yu L, Nan S. Efficacy of different chemotherapy regimens in treatment of advanced or metastatic pancreatic cancer: A network meta-analysis. Journal of Cellular Physiology 2018; 233(4): 3352-3374. doi: 10.1002/jcp.26183
20. Wang XFH, Nie WF, Zhou J,Tan Y, Jiang DW, Hio J. Toxicity of chemotherapy regimens in advanced and metastatic pancreatic cancer therapy: A network meta-analysis. Journal of Cellular Biochemistry 2018; 119(7): 5082-5103. doi: 10.1002/jcb.26210